Abstract:75 Objectives Parkinson disease (PD), multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) are all known to affect dopaminergic neurons and often present with similar clinical features. Dopamine transporter (DAT) imaging can demonstrate presynaptic dopaminergic neuronal loss in PD, MSA and PSP. However, differentiating atypical parkinsonism from PD is often difficult. In this study, we investigated differences in striatal subregional DAT loss in PD, MSA and PSP, as well as the diagnostic value of 11C-CFT PET imaging in the differential diagnosis of parkinsonism. Methods Brain 11C-CFT PET imaging was performed in 219 patients with parkinsonian disorders. The PET images were spatially normalized and a standardized set of regions of interest (ROIs) were defined bilaterally for the caudate, anterior putamen (AP), posterior putamen(PP), ventral putamen (VP), dorsal putamen (DP) and occipital cortex with ScAnVP software. The nondisplaceable binding potential (BPND; defined as the ratio of (striatum-occipital)/occipital radioactivity counts) of each striatal subregion and intersubregional ratio (ISR; defined as the ratio of the BPND of one subregion to that of another subregion) were calculated. After the imaging, these patients were assessed by blinded movement disorders specialists for a mean of 2.3 years before a final clinical diagnosis was made. The accuracy of DAT imaging-based classification was assessed by comparison with the final clinical diagnosis. Results 133 patients had a final clinical diagnosis of PD, 55 MSA, and 31 PSP with severity matched. The BPND of caudate in the PSP group was significantly lower than those in the PD and MSA groups. The ISR of each subregional putamen/caudate in the PSP group was significantly higher than those in the PD and MSA groups. At the cutoff value of 1.16, the AP/C ISR had 87%sensitivity and 93% specificity for differentiating PSP from PD. The classifications were also accurate for PP/C (0.63; 80% sensitivity, 88% specificity), VP/C (1.13; 87% sensitivity, 92% specificity) and DP/C (0.87; 87% sensitivity, 90% specificity) ISRs. At the cutoff value of 1.23, the AP/C ISR had 81% sensitivity and 87% specificity for differentiating PSP from MSA. The classifications were also accurate for PP/C (0.78; 68% sensitivity, 84% specificity), VP/C (1.15; 84% sensitivity, 86% specificity) and DP/C (0.98; 81% sensitivity, 82% specificity) ISRs. The BPND of DP and the ISRs of DP/non-DP subregions in the MSA group were significantly higher than those in the PD group. At the cutoff value of 0.81, the DP/AP ISR had 76% sensitivity and 82% specificity for differentiating MSA from PD. The classifications were also accurate for DP/C (0.76; 71% sensitivity, 75% specificity) and DP/VP (0.87; 76% sensitivity, 76% specificity) ISRs. Conclusions PD, MSA and PSP have different preferential subregional decreases in striatal DAT binding when examined by 11C-CFT PET imaging. The ISRs could provide valuable information to distinguish parkinsonian disorders, even in earlier stages of disease.

Striatal and Extrastriatal Monoaminergic Disruption in Progressive Supranuclear Palsy

Dopamine Transporter Imaging in Progressive Supranuclear Palsy: Severe but Nonspecific to Subtypes

Dopamine Transporter PET Imaging in Patients with Progressive Supranuclear Palsy and Parkinson's Disease

Subregional Patterns of Preferential Striatal DAT Loss Differ in PD, MSA and PSP

Differential cholinergic systems' changes in progressive supranuclear palsy versus Parkinson's disease: an exploratory analysis

Identification of metabolic progression and subtypes in progressive supranuclear palsy by PET molecular imaging

Reproducible Network and Regional Topographies of Abnormal Glucose Metabolism Associated with Progressive Supranuclear Palsy: Multivariate and Univariate Analyses in American and Chinese Patient Cohorts.

Striatal dopaminergic lesions contributed to the disease severity in progressive supranuclear palsy

18F-FP-DTBZ PET/CT detectable associations between monoaminergic depletion in the putamen with rigidity and the pallidus with tremor in Parkinson's disease

Gray matter atrophy in progressive supranuclear palsy: meta-analysis of voxel-based morphometry studies

Clinical Utility of 18F‐APN‐1607 Tau PET Imaging in Patients with Progressive Supranuclear Palsy

Characteristics of Cerebral Glucose Metabolism in Patients with Progressive Supranuclear Palsy

18F-FDG PET Imaging for Characteristics of Cerebral Glucose Metabolism in Patients with Progressive Supranuclear Palsy

18F-FP-CIT PET Imaging and SPM Analysis of Dopamine Transporters in Parkinson’s Disease in Various Hoehn & Yahr Stages

F-18-Fp-Cit Pet Imaging And Spm Analysis Of Dopamine Transporters In Parkinson'S Disease In Various Hoehn & Yahr Stages

Retinal Thinning as a Marker of Disease Severity in Progressive Supranuclear Palsy

Imaging Striatal Microglial Activation in Patients with Parkinson’s Disease

Investigating the Role of 99Mtc-Trodat-1 SPECT Imaging in Idiopathic Parkinson's Disease.

International Consensus on Clinical Use of Presynaptic Dopaminergic Positron Emission Tomography Imaging in Parkinsonism.

Dilated Perivascular Space in the Midbrain May Reflect Dopamine Neuronal Degeneration in Parkinson's Disease.

Dopamine Transporter PET Imaging in Patients with Parkinson Variant of Multiple System Atrophy and Parkinson''s Disease